Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863893 | 0.94 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1TP53BP1OPRM1OPRL1 | |
| SCHEMBL6628090 | 0.89 | OPRM1 (0.43) | L3MBTL3L3MBTL1OPRM1OPRL1MAPK1 | |
| SCHEMBL7320872 | 0.89 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1TP53BP1MBTD1L3MBTL4 | |
| SCHEMBL20160890 | 0.89 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1TP53BP1MBTD1L3MBTL4 | |
| SCHEMBL4213726 | 0.89 | MAPK1 (0.43) | L3MBTL3L3MBTL1TP53BP1OPRM1OPRL1 | |
| SCHEMBL3880193 | 0.87 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1TP53BP1OPRM1OPRL1 | |
| SCHEMBL7634170 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1MAPK1ALDH1A1 | |
| SCHEMBL7633925 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1MAPK1ALDH1A1 | |
| SCHEMBL551401 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1MAPK1ALDH1A1 | |
| SCHEMBL21047675 | 0.86 | OPRM1 (0.46) | OPRM1OPRL1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114320-A1 | FUSED PYRROLIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-2440563-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010144571-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144571-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | L3MBTL3 2741/4885L3MBTL1 2713/4885NOS3 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.